How to access Tezepelumab-ekko from India — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient with severe, uncontrolled asthma may receive a prescription for Tezepelumab-ekko — the non-proprietary designation for tezepelumab, marketed in the United States as Tezspire — from their treating pulmonologist or allergist. It is FDA-approved as add-on maintenance treatment for severe asthma in patients 12 years and older, co-developed by Amgen and AstraZeneca. It is the first and only severe-asthma biologic approved without a phenotype or biomarker restriction, making it an option for high-eosinophil, low-eosinophil, allergic, and non-allergic severe asthma phenotypes alike. In India, availability of this class is still maturing; families whose pulmonologists want a predictable, documented start frequently use the CDSCO personal-use import pathway.

This guide explains the pathway, documentation your physician prepares, indicative timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Tezepelumab binds thymic stromal lymphopoietin (TSLP), an epithelial-cell-derived cytokine that sits upstream of multiple downstream type-2 and non-type-2 inflammatory cascades in asthma (IL-5, IL-4, IL-13, IgE, and beyond). Because TSLP is upstream, blockade reduces exacerbations across asthma phenotypes rather than only in a single-biomarker-selected group. Dosing is 210 mg subcutaneously every four weeks. Your pulmonologist will confirm severe-asthma diagnosis (recurrent exacerbations despite high-dose ICS/LABA, impaired lung function, uncontrolled symptoms), review phenotyping data (blood eosinophils, FeNO, IgE, allergen sensitisation), and decide whether tezepelumab's phenotype-agnostic mechanism fits better than a downstream-targeted biologic given the specific clinical picture.

Is Tezepelumab-ekko legally importable into India?

Yes — through the Central Drugs Standard Control Organisation (CDSCO) personal-use / named-patient import framework under Rule 36 and related provisions of the Drugs and Cosmetics Rules. The mechanism permits import of up to three months' personal supply for a named patient under a registered medical practitioner's prescription, with customs clearance supported by the prescription, physician's letter, and product documentation. It is well-established for specialty biologics where local supply or registration timing does not match the clinical plan.

How the pathway works, step by step

1. Consultation with your treating pulmonologist or allergist. Severe-asthma confirmation, exacerbation history over the prior 12 months, FEV1 and asthma control test scores, and phenotype workup.
2. Biologic selection. Your physician weighs tezepelumab against phenotype-targeted alternatives (anti-IL-5, anti-IL-5R, anti-IgE, anti-IL-4Rα) given the specific clinical picture — TSLP blockade is particularly attractive for mixed or low-biomarker phenotypes, or after suboptimal response to a downstream biologic.
3. Prescription and import letter. Your physician issues the prescription and a clinical letter describing indication, dosing schedule, and personal-use rationale.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure tezepelumab from authorised distribution under DSCSA.
5. Cold-chain shipment to India. The product ships under validated 2-8 °C conditions with temperature logging; Reserve Meds handles customs documentation with the importing agent.
6. Arrival and administration. First dose administered under physician observation per labeling; subsequent monthly doses administered by clinician, trained caregiver, or patient.

What documentation your physician needs

• Clinical rationale letter confirming severe-asthma diagnosis, exacerbation history, prior controller regimen, and tezepelumab as the indicated add-on
• Verification of Medical Council of India / NMC registration
• Spirometry results (FEV1, reversibility)
• Phenotyping workup (blood eosinophils, FeNO, IgE, allergen sensitisation)
• Planned dosing schedule and follow-up cadence
• Patient identifier and residential address for import clearance

Reserve Meds provides a physician documentation kit that bundles the templates CDSCO and customs expect to see for severe-asthma biologic personal imports, including the phenotype-selection rationale annex.

Typical costs and indicative timing

Tezepelumab's US cash-pay drug-only reference range in 2026 sits at roughly USD 3,500-4,500 per 210 mg SC dose (monthly supply). International cold-chain logistics, CDSCO documentation handling, customs clearance, and concierge coordination are quoted separately. Reserve Meds issues a full transparent delivered quote at intake so your family sees one landed number before committing. These ranges are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 7-14 days from the moment complete documentation is in hand. Maintenance doses ship monthly on a rolling calendar.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For tezepelumab specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from authorised channels.
• Documentation. Regulatory package for your physician, CDSCO import documentation, and customs-clearance support.
• Logistics. Validated 2-8 °C cold-chain shipment with temperature logging.
• Concierge case lead. A named point of contact coordinating monthly refills.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating pulmonologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with a valid prescription and supporting physician letter. See our trust and compliance page for our methodology.

Why choose tezepelumab rather than an anti-IL-5 or anti-IgE biologic? Tezepelumab is the only severe-asthma biologic approved without a phenotype restriction. The TSLP mechanism sits upstream of multiple downstream pathways, so it is attractive for mixed phenotypes, low-biomarker severe asthma, or patients who have had suboptimal response to a downstream biologic. Your pulmonologist decides based on the specific clinical picture.

What if I have already tried Fasenra or Nucala? Tezepelumab's upstream mechanism is often the next option for patients with persistent severe asthma despite an anti-IL-5-class biologic. Your pulmonologist will document the switch rationale.

Can my child receive it? The FDA approval covers patients 12 years and older. Younger patients are outside current labeling; your physician decides.

Will private insurance cover this? Cash-pay is the default. Some Indian private insurers and corporate plans consider named-patient imports case by case; we supply documentation for your submission but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for tezepelumab coordination in India.

Add me to the Tezepelumab-ekko waitlist

---

Examples and timings above are composite illustrations drawn from published sources and typical personal-use import patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.